Articles by Lynn D. Torbeck - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Lynn D. Torbeck

Compositing Samples and the Risk to Product Quality

Compositing samples is appropriate under certain circumstances but raises caveats on how and when it should be applied.
May 2, 2013

Compositing samples is appropriate under certain circumstances but raises caveats on how and when it should be applied.

Time to Revise ICH Q9

A change in terminology could emphasize patient protection.
Dec 2, 2012

A change in terminology could emphasize patient protection.

Tools in Waiting: Time for Evolutionary Operation

Real-time experimentation may offer continuous process improvement.
Oct 2, 2012

Real-time experimentation may offer continuous process improvement.

A Statistical Review of ICH Q10 Pharmaceutical Quality System

Applying the recommendations of ICH Q10 to statistical analysis can help prevent product recalls.
Aug 2, 2012

Applying the recommendations of ICH Q10 to statistical analysis can help prevent product recalls.

Placket–Burman Designs

Applying current principals to traditional factorial designs.
Jul 2, 2012

Applying current principals to traditional factorial designs.

Representative Sampling

Understanding the differences between convenience, target, and self-selected samples.
Apr 2, 2012

Understanding the differences between convenience, target, and self-selected samples.

Reducing Common Cause Variation

Where is the variability coming from and what have we done to minimize it?
Feb 2, 2012

Where is the variability coming from and what have we done to minimize it?

Out-of-Specification Sample-Size Confusion

Precedents set in the historic Barr case continue to raise questions over suitable sample-size criteria.
Dec 2, 2011

Precedents set in the historic Barr case continue to raise questions over suitable sample-size criteria.

The Matrixx Zicam Verdict

The authors summarize the Matrixx Initiatives, Inc. v. Siracusano case's implications for industry.
Oct 2, 2011

The authors summarize the Matrixx Initiatives, Inc. v. Siracusano case's implications for industry.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here